FRANKLIN LAKES, N.J., Oct. 14, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial launch of the first in a family of high-throughput, robotics-compatible reagent kits that will enable automation to ensure greater consistency and increased efficiency of large-scale, single-cell discovery studies..

全球领先的医疗技术公司BD（Becton, Dickinson and Company）（纽约证券交易所股票代码：BDX）今天宣布，高通量、机器人兼容试剂盒系列中的首款试剂盒正式投入商业应用，该试剂盒将实现自动化，以确保大规模单细胞发现研究具有更高的一致性和效率。

The automated solution from the BD and Hamilton collaboration standardizes traditionally manual processes and speeds the generation of material for genetic sequencing. The solution includes the newly released BD® OMICS-One XT WTA Assay and the Hamilton® Microlab™ NGS STAR automated liquid handling platform.

BD和汉密尔顿合作公司的自动化解决方案标准化了传统的手动过程，并加快了基因测序材料的生成。该解决方案包括最新发布的BD®OMICS One XT WTA分析和Hamilton®Microlab™NGS STAR自动液体处理平台。

Because the NGS STAR is already installed in many laboratories and facilities worldwide, more researchers, processing samples across an array of genomics applications, can easily integrate the new automation-ready BD® assay into existing workflows..

由于NGS STAR已经安装在全球许多实验室和设施中，因此更多研究人员可以通过一系列基因组学应用程序处理样本，轻松将新的自动化就绪BD®分析集成到现有工作流程中。。

In single-cell discovery studies involving genetic material, constructing preparatory material otherwise called 'DNA libraries' is an essential early step. Historically, such preparations have been labor-intensive and time-consuming processes, with numerous manual steps that often lead to variability of results, compromised data quality, limited throughput, high cost and long turnaround times..

在涉及遗传物质的单细胞发现研究中，构建准备材料（也称为“DNA文库”）是必不可少的早期步骤。从历史上看，这些准备工作是劳动密集型和耗时的过程，有许多手动步骤，通常会导致结果的可变性，数据质量受损，吞吐量有限，成本高和周转时间长。。

'By automating the complex library preparation process, researchers can scale their sample throughput and expect more consistent results, minimizing the variability introduced by manual procedures,' said Steve Conly, worldwide president of BD Biosciences. 'This standardization is crucial for the reproducibility of experiments, which is a cornerstone of scientific research.

BD Biosciences全球总裁史蒂夫·康利（SteveConly）说：“通过自动化复杂的文库制备过程，研究人员可以扩大样本吞吐量，并期望得到更一致的结果，从而最大程度地减少手动程序带来的变异性。”这种标准化对于实验的可重复性至关重要，这是科学研究的基石。

The integration of Hamilton's robotics with BD's robotics-ready reagent kits can streamline workflows, reduce the potential for human error, and accelerate the pace of discovery in critical areas such as oncology and immunology.'.

汉密尔顿机器人技术与BD机器人就绪试剂盒的集成可以简化工作流程，减少人为错误的可能性，并加快肿瘤学和免疫学等关键领域的发现步伐。”。

Matt Hamilton, CEO at Hamilton added, 'Hamilton's advanced automated solutions streamline scientific workflows, maximizing the potential of single-cell multiomics research. Our partnership with BD furthers our mission to provide innovative technologies that accelerate groundbreaking discoveries in science and medicine.'.

汉密尔顿首席执行官马特·汉密尔顿补充道：“汉密尔顿的先进自动化解决方案简化了科学工作流程，最大限度地发挥了单细胞多组学研究的潜力。我们与BD的合作进一步推动了我们的使命，即提供创新技术，加速科学和医学领域的突破性发现。”。

The BD® OMICS-One XT Library Preparation Reagent Kits and Hamilton Microlab NGS STAR automated liquid handling platform and applications are commercially available globally. The robotics liquid-handling platform is available for purchase from Hamilton, and the reagent kits are available for purchase from BD representatives, or in some regions, through BD's e-commerce portal.

BD®OMICS One XT文库制备试剂盒和Hamilton Microlab NGS STAR自动液体处理平台和应用程序可在全球范围内商购。机器人液体处理平台可从汉密尔顿购买，试剂盒可从BD代表处或在某些地区通过BD的电子商务门户购买。

About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers.

关于BDBD是世界上最大的全球医疗技术公司之一，正在通过改进医疗发现、诊断和护理服务来促进世界健康。该公司通过开发创新技术、服务和解决方案来支持医疗保健前线的英雄，这些技术、服务和解决方案有助于推进患者的临床治疗和医疗保健提供者的临床过程。

BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics.

BD及其70000多名员工充满热情并致力于帮助提高临床医生护理过程的安全性和效率，使实验室科学家能够准确检测疾病，并提高研究人员开发下一代诊断和治疗方法的能力。

BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

BD在几乎每个国家都有业务，并与世界各地的组织合作，以解决一些最具挑战性的全球健康问题。通过与客户密切合作，BD可以帮助提高成果，降低成本，提高效率，提高安全性并扩大医疗保健的范围。